EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS

恶性疟原虫 LSA-1 亚基的表达

• 批准号: 6293636
• 负责人: DAVID E CLEMENTS
• 金额: $ 17.72万
• 依托单位: HAWAII BIOTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-30 至 2003-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6293636
• 关键词: Plasmodium falciparum; gene expression; human tissue; laboratory mouse; malaria vaccines; protein engineering; protein purification; protozoal antigen; protozoal genetics; recombinant proteins; vaccine development; vector vaccine

DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a tropical parasitic disease that is a significant health threat. Each year, approximately 500 million people become infected and 2 to 3 million die worldwide. There is a great need to control the spread of this disease. Recently, the development of malaria vaccines has focused on the use of recombinant DNA technology. The inclusion of pre-erythrocytic antigens, such as the liver stage antigen-1 (LSA-1), is important in the development of a successful multi-component malaria vaccine. To date, most efforts to develop LSA-1-based vaccines have focused on the use of defined peptide sequences. Phase I research will test the feasibility of efficiently expressing truncated forms of the Plasmodium falciparum LSA-1 antigen. These recombinant subunits have the potential to provide a broader immune response than the synthetic peptides tested. The expression system proposed for this research has been shown to express high levels of recombinant proteins, including a malaria erythrocyte stage vaccine candidate antigen. The successful expression of high levels of a liver stage candidate vaccine antigen with appropriate antigenic and immunogenic characteristics could contribute to the development of a safe, efficacious and cost effective vaccine for malaria. PROPOSED COMMERCIAL APPLICATION: Malaria poses a significant health threat. Annually, approximately 500 million people become infected and 1 to 2 million die. Currently, there is no vaccine for malaria. The proposed research will test the feasibility of expressing and secreting a malaria subunit targeted for vaccine development. Successful expression of high levels of this subunit could contribute to the development of a safe, efficacious and cost effective malaria vaccine.

描述：（改编自申请人的摘要）疟疾是热带 寄生疾病是重大健康威胁。大约每年 5亿人被感染，全球2至300万人死亡。有一个 控制这种疾病的传播非常需要。最近，发展 疟疾疫苗专注于使用重组DNA技术。这 包括肉毒少细胞前抗原，例如肝脏抗原-1 （LSA-1），在成功的多组分的发展中很重要 疟疾疫苗。迄今为止，开发基于LSA-1的疫苗的大多数努力都 专注于使用定义的肽序列。第一阶段研究将测试 有效表达疟原虫的截短形式的可行性 恶性LSA-1抗原。这些重组亚基有可能 与所测试的合成肽相比，提供更广泛的免疫反应。这 为这项研究提出的表达系统已被证明表达高 重组蛋白的水平，包括疟疾红细胞阶段疫苗 候选抗原。高水平肝阶段的成功表达 具有适当抗原和免疫原性的候选疫苗抗原 特征可能有助于开发安全，有效和 疟疾的成本有效疫苗。 拟议的商业应用： 疟疾构成了重大的健康威胁。每年，大约有5亿人被感染，1至200万人死亡。目前，疟疾尚无疫苗。拟议的研究将测试表达和分泌针对疫苗开发的疟疾亚基的可行性。高水平的该亚基的成功表达可能有助于开发安全，有效且具有成本效益的疟疾疫苗。